Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Biomed Pharmacother. 2023 Oct;166:115285. doi: 10.1016/j.biopha.2023.115285. Epub 2023 Aug 17.
Heart failure (HF) is a complex clinical syndrome with impaired ventricular ability due to structural or functional cardiac disorders. A traditional Chinese formula named Xinshubao tablet (XSB) is reported to protect cardiomyocytes and decrease the risk of HF clinically; however, the underlying mechanism of XSB on decreasing HF risk is not elucidated yet. Therefore, our study aimed to investigate the therapeutic efficacy and underlying mechanism of XSB by using HF model rats and H9c2 cells with oxygen glucose deprivation. Echocardiographic and pathological features of animal experiment showed that XSB treatment effectively improved cardiac function and ameliorated myocardial injury after 4 weeks of treatment. Cellular experiments indicated that XSB pretreatment significantly inhibited apoptosis and increased mitochondrial energy metabolism. Furthermore, in vivo and in vitro experiments both demonstrated that XSB suppressed oxidative stress and inflammatory response. Our results further revealed that the potential protective mechanism of XSB was closely associated with the DCN/PPARα/PGC-1α/P300 signaling pathway. Our findings provide novel mechanistic insights for HF treatment and a pharmacological basis for the therapeutic application of XSB against cardiovascular disorders.
心力衰竭（HF）是一种复杂的临床综合征，由于心脏结构或功能障碍导致心室功能受损。一种名为心舒宝片（XSB）的中药配方据称具有保护心肌细胞和降低心力衰竭风险的作用，但 XSB 降低心力衰竭风险的潜在机制尚未阐明。因此，我们的研究旨在通过 HF 模型大鼠和氧葡萄糖剥夺的 H9c2 细胞来研究 XSB 的治疗效果和潜在机制。动物实验的超声心动图和病理学特征表明，XSB 治疗 4 周后可有效改善心功能，减轻心肌损伤。细胞实验表明，XSB 预处理可显著抑制细胞凋亡，增加线粒体能量代谢。此外，体内和体外实验均表明，XSB 可抑制氧化应激和炎症反应。我们的研究结果进一步揭示了 XSB 的潜在保护机制与 DCN/PPARα/PGC-1α/P300 信号通路密切相关。本研究结果为 HF 治疗提供了新的机制见解，并为 XSB 在心血管疾病治疗中的应用提供了药理学依据。
